Marshall Wace acquired 362,690 Novavax shares in Q2, while the company missed Q2 EPS expectations.

Marshall Wace LLP acquired 362,690 shares of Novavax (NASDAQ: NVAX) worth approximately $4.59 million in Q2, amid strong institutional interest, with 53.04% of shares held by such investors. Novavax reported a Q2 EPS of $0.99, missing expectations of $1.82. Its market cap is $1.73 billion, with a 52-week price range of $3.53 to $23.86. Analysts show mixed ratings, with a consensus "Hold" and an average price target of $15.80.